Microreviews in Cell and Molecular Biology 2022

CAR T-cell therapy: Pathways of Resistance

Author: Fiona Byrd
Major: Biochemistry & Molecular Biology
Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, OK 74078, USA

Key Words:
CAR T cell, lymphoblastic leukemia

- **Successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials involving patients with pre-B cell acute lymphoblastic leukemia and other cancer types**
- **Trials resulted in rapid FDA approvals of anti-CD19 CAR T cell products for types of B cell lymphoma**
- **However, remissions will be brief in a substantial number of patients owing to poor CAR T cell persistence and/or cancer cell resistance resulting from antigen loss or modulation**

Introduction

Cancer is a prevalent and persistent disease that plagues society, yet there is strong evidence to suggest that CAR T-cell therapy is an effective tool to aid in promoting remission in cancer patients – specifically patients afflicted with B-cell acute lymphoblastic leukemia or large B-cell lymphoma. In recent years, CAT T-cell therapy has gained both credibility and traction in the scientific community for the ability of the treatment to promote remission by employing a form of cell-based gene therapy that consists of altering T cells to recognize and destroy cancer cells. The treatment – as it is continuously refined – could harbor the potential to be an effective cancer treatment that works with immune cells, rather than against them.

Immune cells both recognize and eliminate cancer cells and mutated cells. TCR structure and MHC presentation determine how T Cells are used to identify the TAAs expressed by cancer cells. CAR-T cells, however, only depend on the structure of CAR. Cytotoxicity of T cells and binding specificity of antigen are both qualities possessed by CAR-T cells. TAA are utilized in the treatment of neoplasms that are hematological in nature, the most commonly-applied TAA being CD19. When injected into the body CD19 cells attack both normal and CD19 cells.

CAR-T cells utilize proliferation and phosphorylation to initiate activation. Cytokine secretion and cytotoxicity are the main sources of notable cancer response. An essential role is played by CD8-positive CAR-T cells in terms of the destruction of cancer cells. An assisting role is executed by CD4-positive CAR-T cells in this process. Specifically, these cells aid in strengthening the reaction of the immune system to the presence of malignant cells. Granzyme is secreted via CAR-T cells in order to perform cytotoxicity and destroy tumor cells. CAR-T cells release cytokines in order to improve the clearance of tumor cells.

Recent Progress

Although a number of notable research studies have been performed utilizing chimeric antigen receptor (CAR) T cell immunotherapy, according to one particular study CAR T-cell therapy has been shown to be a highly effective form of adoptive cell therapy in cases of B cell acute lymphoblastic leukemia or large B cell lymphoma. This is evidently clear in remission rates displayed by patients with both cancer afflictions. CAR T cell therapy works in this context by employing gene "reprogramming" of exhaustion versus memory. This method in tandem with T cell fitness works to determine a response to CD19-targeted CAR T cells in chronic

lymphocytic leukemia. It has also been noted in scientific literature that CAR T cell therapy – in a general sense – is an effective solution for relapsed or refractory tumors, including hematological malignancies. CAR T cell therapy remains a promising treatment route given the ability for the treatment to be tailored to the specific needs of individual patients.

Research has been done applying CAR-T cytotherapy to all forms of acute lymphoblastic leukemia. This treatment has been shown to be effective in cases of refractory B-CD19 or cases of relapse. Studies have provided compelling evidence to suggest that CD19 is a nearly ideal target for the treatment of surface-level B-cells. A CAR-T cell drug that targets CD19 specifically has been developed by researchers and subsequently approved by the FDA.

Vehicle T cytotherapy has gained promising remedial impacts in treatment of hematological malignancies, for example ALL, CLL and NHL. Poisonous impacts are frequently gone with customary corrective impact when patients got CAR-T cells. Further improvement is obstructed with loads of antagonistic impacts that are displayed such as the arrival of cytokine, neurotoxicity, cancer lysis condition and different poison levels. Furthermore, the overall remedial impact of CAR-T cytotherapy is decreased by the high pace of backslide and the predominant clinical application is impeded by the intricacy of creation and significant expense.

It should be noted that “antigen escape” seen in some cancer cells decreased patient sensitivity to CD19-specific CAR-T cells. Researchers have hypothesized that this problem can be addressed via the addition of molecular targets on tumor cells must be discovered. Researchers have already initiated the process of resolving this issue with studies exploring CD20 as a potential target and producing promising results. It has also been noted that CD123 and CD22 could serve as targets pending further confirmation of their effectiveness.

Currently, the most traditional and common therapy for a variety of forms of lymphoma – including anaplastic large cell lymphoma (ALCL), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL) are monoclonal antibodies and chemotherapy regimens. Although worsened disease was experienced still in some cases following these treatments, both therapies have displayed clinical success. Nevertheless, changes are needed in terms of therapies that provide a greater success rate in regard to these afflictions. Improvements are needed, especially, in cases involving patients with poor or complex prognoses after treatment via traditional therapies. In regard to cases of lymphoma treated with CD19 CAR-T cells, it has been determined that approximately 75% of these patients were able to obtain PR. As referenced earlier, a number of treatment routes are being explored by researchers. These treatment routes utilize different targets, bearing in mind that CD20 is prevalent in many cases of lymphoma involving B cells. A number of studies have produced promising results in terms of the efficacy of CD20 as a target.

Another treatment utilizing CAR-T cells in cases of multiple myeloma (MM) – a hematologic refractory tumor that can lead to instances of anemia, suppression of the immune system, renal failure, bone lesions, and hypercalcemia. Molecular deformities of myeloma and cellular heterogeneity make this disease almost incurable by conventional treatment pathways involving autologous HSCT or chemotherapy. CAR-T cytotherapy utilizing CD19 as a target failed to adequately eliminate myeloma cells yet has proven itself to be an excellent treatment route for virtually all hematologic malignancies.

Discussion

Historically, the treatment of cancer has included a combination of immunotherapy, chemotherapy, surgery, and radio therapy. The conventional treatment for hematologic malignancies has been HSCT, although this was once chemotherapy. However, new immunotherapies have developed in recent years showing promising effectiveness in treating cases of hematologic malignancies. Promise is seen, specifically, in the form of CAR-T cell therapy as an alternative mode of therapy for malignant tumors. As such the potential for curing refractory and relapsed malignant tumors in these instances has certainly improved. Further research involving small-molecule therapy is being explored in tandem with increasing the therapeutic efficacy of this treatment option. As a result of this combinational approach, improved therapies may arise. A CAR-T combined with a checkpoint blocking antibody or small molecule inhibitor may present extraordinary therapeutic effects and improve the cure rate for hematological malignancies. Researchers attempt to enhance the therapeutic properties of CAR-T products by screening small molecules to incorporate into the manufacturing process.

In cases of CD19-negative leukemia, chimeric antigen receptor therapy has shown to be somewhat limited. Although the initially FDA approved anti-CD19 CAR-T treatment has produced significant results, setbacks have been experienced, including resistance and high relapse rates. Due to these setbacks, it has become necessary to find CAR-T cells that are more suitable for therapeutic purposes. Innovations in the structure and manufacturing

of CAR-T cells have improved the persistence and effectiveness of this treatment. Improvements have been observed particularly with the development of fourth-generation CAR-T cells. Combining fourth-generation and next-generation CAR-T cells with an immune modifier will not be limited by cytotoxic effects and can be a successful tool for overcoming the tumor microenvironment.

In cancer therapy, immunotherapy has demonstrated satisfactory clinical curative effects and is regarded as a desirable method. Recently, immunotherapies such as gene therapy, antibody therapy, adoptive cell therapy, and other therapies have undergone intensive research and achieved dramatic breakthroughs. Genetically modified CAR-T cytotherapy has a distinguished effect in hematopoietic malignancies, especially among adoptive cell therapies. As of late, Tecartus (brexucabtagene autoleucel), as the third CAR-T cells drug, was supported by the FDA for the treatment of MCL. Notwithstanding of various empowering results, CAR-T cell treatment were high cost, make complex the expectation of its security actually stays challenging.

Recognizable proof of strong biomarkers in comparing hematopoietic malignancies is one of the procedures to work on remedial impact. B cell actuating factor receptor (BAFF-R) exhibited convincing preclinical outcomes and showed cytotoxicity against various human lymphoma and leukemia cell lines, including CD19-negative variations. It is basic for battling B cell malignancies when CD19-designated antigen of growth cells is lost. Considering the expense and work escalation, studies started focusing on allogeneic CAR-T implantation and some has continuous clinical stage preliminaries. The cytotoxicity after CAR-T cells mixture is generally a test that blocks the further turn of events. However, there is one thing we ought to realize that the modalities of CAR-T cells treatment are still in their beginning phases and certainly the broad utilization of CAR-T cells treatment is confronted with a few issues in logical information before it is generally applied.

References

Almåsbak, H., Aarvak, T., & Vemuri, M. C. (2016). CAR T cell therapy: a game changer in cancer treatment. *Journal of immunology research*, *2016*.

Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H., & O'Rourke, D. M. (2018). CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. *Neuro-oncology*, *20*(11), 1429-1438.

Bupha-Intr, O., Haeusler, G., Chee, L., Thursky, K., Slavin, M., & Teh, B. (2021). CAR-T cell therapy and infection: a review. *Expert Review of Anti-infective Therapy*, *19*(6), 749-758.

Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., ... & Zhou, J. (2019). Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. *Frontiers in Oncology*, 1237.

Han, D., Xu, Z., Zhuang, Y., Ye, Z., & Qian, Q. (2021). Current progress in CAR-T cell therapy for hematological malignancies. *Journal of Cancer*, *12*(2), 326.

Jacoby, E., Shahani, S. A., & Shah, N. N. (2019). Updates on CAR T-cell therapy in B-cell malignancies. *Immunological reviews*, *290*(1), 39-59.

Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017). Global manufacturing of CAR T cell therapy. *Molecular Therapy-Methods & Clinical Development*, *4*, 92-101.

Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020). Engineering strategies to overcome the current roadblocks in CAR T cell therapy. *Nature reviews Clinical oncology*, *17*(3), 147-167.

Shroeder, Insa S. "Potential of Pluripotent Stem Cells for Diabetes Therapy". Current Diabetes Reports. 5 (2012): 490-498.

Teoh, P. J., & Chng, W. J. (2021). CAR T-cell therapy in multiple myeloma: More room for improvement. *Blood Cancer Journal*, *11*(4), 1-18.

Wang, Z., Wu, Z., Liu, Y., & Han, W. (2017). New development in CAR-T cell therapy. *Journal of hematology & oncology*, *10*(1), 1-11.

